

Specimen ID:
 Control ID:

Acct #:

Phone:

Rte: 00

Patient Details

 DOB:
 Age(y/m/d):
 Gender: SSN:
 Patient ID:

Specimen Details

 Date collected:
 Date received:
 Date entered:
 Date reported:

Physician Details

 Ordering:
 Referring:
 ID:
 NPI:

General Comments & Additional Information
Alternate Control Number:
Total Volume:
Alternate Patient ID:
Fasting:
Ordered Items

HCV FibroSure; Venipuncture

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
-------	--------	------	-------	--------------------	-----

HCV FibroSure

HCV FibroSURE Results:

Fibrosis Score	0.62	High		0.00 - 0.21	
Fibrosis Stage					

F3-Bridging fibrosis with many septa

Necroinflammat Activity Score	0.77	High		0.00 - 0.17	
Necroinflammat Activity Grade					

A3-Severe activity

 .
 Analysis:

Alpha 2-Macroglobulins, Qn	306	High	mg/dL	110 - 276
Haptoglobin	117		mg/dL	34 - 200
Apolipoprotein A-1	110		mg/dL	101 - 178
Bilirubin, Total	0.5		mg/dL	0.0 - 1.2
GGT	38		IU/L	0 - 65
ALT (SGPT) P5P	128	High	IU/L	0 - 55

 .
 Interpretations:

Quantitative results of 6 biochemical tests are analyzed using a computational algorithm to provide a quantitative surrogate marker (0.0-1.0) for liver fibrosis (METAVIR F0-F4) and for necroinflammatory activity (METAVIR A0-A3).

Fibrosis Scoring:

<0.21 = Stage F0 - No fibrosis
 0.21 - 0.27 = Stage F0 - F1
 0.27 - 0.31 = Stage F1 - Portal fibrosis
 0.31 - 0.48 = Stage F1 - F2
 0.48 - 0.58 = Stage F2 - Bridging fibrosis with few septa
 0.58 - 0.72 = Stage F3 - Bridging fibrosis with many septa
 0.72 - 0.74 = Stage F3 - F4
 >0.74 = Stage F4 - Cirrhosis

Necroinflamm Activity Scoring:

Patient:
DOB:

Patient ID:

Control ID:

Specimen ID:
Date collected:

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
<0.17	= Grade A0	- No Activity			
0.17 - 0.29	= Grade A0	- A1			
0.29 - 0.36	= Grade A1	- Minimal activity			
0.36 - 0.52	= Grade A1	- A2			
0.52 - 0.60	= Grade A2	- Moderate activity			
0.60 - 0.62	= Grade A2	- A3			
>0.62	= Grade A3	- Severe activity			

Limitations:

The negative predictive value of a Fibrotest score <0.31 (absence of clinically significant fibrosis) was 85% when compared to liver biopsy in 1,270 HCV infected patients with a 38% prevalence of significant liver fibrosis (F2, 3 or 4). The positive predictive value of a Fibrotest score >0.48 (F2, 3, 4) was 61% in that same patient cohort. HCV FibroSURE is not recommended in patients with Gilbert Disease, acute hemolysis (e.g. HCV ribavirin therapy mediated hemolysis) acute hepatitis of the liver, extra-hepatic cholestasis, transplant patients, and/or renal insufficiency patients. Any of these clinical situations may lead to inaccurate quantitative predictions of fibrosis and necroinflammatory activity in the liver.

Comment:

This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. For questions regarding this report please contact customer service at 1-800-788-9223.